Corrigendum to 'Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models' [Eur J Cancer 61 (2016) 20-28].

Autor: Tsimafeyeu I; Ruspharmtech LLC, Saint Petersburg, Russia. Electronic address: tsimafeyeu@ruspharm.com., Ludes-Meyers J; Altogen Labs, Austin, TX, USA., Stepanova E; N.N. Blokhin Russian Cancer Research Center, Moscow, Russia., Daeyaert F; FD Computing, Beerse, Belgium., Khochenkov D; N.N. Blokhin Russian Cancer Research Center, Moscow, Russia., Joose JB; EcoSynth, Oostende, Belgium., Solomko E; N.N. Blokhin Russian Cancer Research Center, Moscow, Russia., Van Akene K; EcoSynth, Oostende, Belgium., Peretolchina N; N.N. Blokhin Russian Cancer Research Center, Moscow, Russia., Yin W; Altogen Labs, Austin, TX, USA., Ryabaya O; N.N. Blokhin Russian Cancer Research Center, Moscow, Russia., Byakhov M; Moscow Clinical and Research Center, Moscow, Russia., Tjulandin S; N.N. Blokhin Russian Cancer Research Center, Moscow, Russia.
Jazyk: angličtina
Zdroj: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2017 Jan; Vol. 70, pp. 156. Date of Electronic Publication: 2016 Dec 03.
DOI: 10.1016/j.ejca.2016.11.001
Databáze: MEDLINE
Externí odkaz: